

9 January 2020

s22
s22 ANZ Commercial Operations
CSL Behring
Via Email s22 @cslbehring.com.au

Dear s22

PROPOSED CHANGE TO PLASMA-FOR-FRACTIONATION

I am writing to you in accordance with the agreement between the Australian Red Cross Society and CSL Limited (now CSL Behring) which s47(1)(b), to advise you of a proposed change to our deferral practices which may impact on plasma-for-fractionation.

Subject to approval from the Therapeutic Goods Administration (TGA), Australian Red Cross Lifeblood intends to reduce the deferral period for donors with a sexual-activity-based risk factor from twelve to three months since the last sexual contact. As you know, we have been consulting with CSL Behring about the proposed change over the last six months in accordance with s47(1)(b).

Lifeblood has recently submitted this proposed change to the TGA – and we will continue to advise you of any updates in the regulatory process. In our view, subject to approval from the TGA, our plasma-for-fractionation will continue to meet the Plasma Specifications in the Agreement after adoption of the deferral change.

s47(1)(b)

If you or your team have any queries about this change, please contact s22
(s22) on s22 @redcrossblood.org.au or s22 Corporate Strategy
& Transformation) on s22 @redcrossblood.org.au

Yours sincerely

s22

cc. s22 Regional Contract Fractionation ANZ, CSLB
s22 @cslbehring.com.au)
s22 National Blood Authority
s22 Blood & Infectious Diseases Safety Unit, TGA